Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual steering committee members.
Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging
Rheumatology Expert, 2022 DOI: 10.1093/rheumatology/keac104
Maksymowych et al., evaluated the efficacy of Ixekizumab in patients with radiographic axial spondyloarthritis (r-axSpA) with and without objective measures of inflammation.
Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
doi: 10.1136/annrheumdis-2021-222027
This analysis aimed to report the safety profile of ixekizumab for the PsA SPIRIT programme. The overall safety profile and tolerability of ixekizumab are consistent with the previously known safety profile in patients with PsA.